Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition

JCI Insight(2023)10.1172/jci.insight.164296Source: DataRank Database

Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition is a research paper published in JCI Insight (2023). On theSindex it has a DataRank of 0. It has been cited 55 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access55 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)OA: goldTopics (46)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Yael Riahi,Ifat Abramovich ORCID,Ofri Mosenzon ORCID,Bella Agranovich,Liat Kadosh

Live enrichment

PubMed:36809274 PMC:PMC10132155

BLRD VA

Grant: I01 BX002728

Foundation for the National Institutes of Health

Grant: R01-DK073716

European Foundation for the Study of Diabetes

Grant: 94863

Israel Science Foundation

Grant: 398/20

National Institutes of Health

Grant: 2R01DK073716-07A1

Akt/mTOR signaling and regulation of cell cycle in beta-cells

goldLicense: cc-by

publisherhttps://doi.org/10.1172/jci.insight.164296

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10132155/pdf/jciinsight-8-164296.pdf

repositoryhttps://doaj.org/article/49358b6776da4385b24f9cb12f16a15f

Europe_PMChttps://europepmc.org/articles/PMC10132155

Europe_PMChttps://europepmc.org/articles/PMC10132155?pdf=render

Fields of Study

0301 basic medicine03 medical and health sciences

MeSH Terms

AnimalsMiceDiabetes Mellitus, ExperimentalSodiumBetaineBenzhydryl CompoundsGlucosidesGlucoseMethionineSodium-Glucose Transporter 2AMP-Activated Protein KinasesSodium-Glucose Transporter 2 Inhibitors

Keywords

MetabolismSignal transductionDiabetesTherapeuticsglucose metabolismMedical SciencesBiochemical PhenomenaBioinformatics610AMP-Activated Protein KinasesBiomedical InformaticsDiabetes Mellitus, ExperimentalExperimentalMiceEndocrinologyMethionineSodium-Glucose Transporter 2GlucosidesDiabetes MellitusMedical SpecialtiesMedicine and Health SciencesAnimalsBenzhydryl CompoundsSodium-Glucose Transporter 2 Inhibitorsand NutritionSodiumRBetaineGlucoseand MetabolismMedicineResearch Article

Additional file 7 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648928.v1figshare

Additional file 7 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648928figshare

Additional file 8 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648931.v1figshare

Additional file 8 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648931figshare

Additional file 9 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648934.v1figshare

Additional file 9 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648934figshare

Additional file 12 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648943.v1figshare

Additional file 12 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648943figshare

Additional file 13 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648946.v1figshare

Additional file 13 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648946figshare

Additional file 14 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648949figshare

Additional file 14 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648949.v1figshare

Additional file 11 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648940figshare

Additional file 10 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648937.v1figshare

Additional file 10 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648937figshare

Additional file 11 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648940.v1figshare

Additional file 3 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648916.v1figshare

Additional file 6 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648925.v1figshare

Additional file 3 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648916figshare

Additional file 4 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

10.6084/m9.figshare.26648919figshare